Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. ("RGLS"), sold 8,050 shares at $7.08 ($54K) on 2014-07-09, disclosed to the SEC on 2014-07-11.
Scheduled sale ($54k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.08 | 1,800 | $13K | 23.5% |
| 2 | $6.69 | 4,500 | $30K | 55.6% |
| 3 | $6.48 | 1,750 | $11K | 20.9% |
| Total | $6.73 avg | 8,050 | $54K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |